1. Introduction {#s1}
===============

It has been shown that hyperglycemia, also called stress hyperglycemia or stress diabetes, associated with critical illness, even in patients without diabetes mellitus (DM), is a consequence of many factors, including increased cortisol, catecholamines, glucagon, growth hormone, gluconeogenesis, and glycogenolysis.[@b1] Acute hyperglycemia on admission is common among patients with ST-elevation myocardial infarction (STEMI) and is one of the important predictors of in-hospital and long-term adverse events.[@b2]--[@b7] Although previously diagnosed DM has been only 20% to 25% in patients with STEMI, the rate of hyperglycemia may reach up to 50%.[@b4] When oral glucose tolerance testing is applied to acute myocardial infarction (MI) patients without a history of DM, the prevalence of type-2 DM and impaired glucose tolerance may exceed 65%.[@b8] Aging is characterized with reduced response capacity to various unusual conditions. The fact that glucose levels after glucose loading tend to be higher in healthy elderly compared to younger subjects render these patients prone to stress diabetes.

Along with the global aging phenomenon, elderly patients represent an increasing population in MI patients and there is limited data on how admission blood glucose (ABG) levels affect the prognosis in this population. The aim of this study was to assess whether ABG levels in STEMI patients older than 65 years is a prognostic indicator of in-hospital and long-term adverse cardiovascular events.

2. Methods {#s2}
==========

2.1. Patient population {#s2a}
-----------------------

In a prospective design, 677 consecutive patients, who were ≥ 65 years and underwent primary percutaneous coronary intervention (PCI) for STEMI in our thoracic and cardiovascular surgery center between October 2003 and March 2008 were included. The study inclusion criteria were as follows: electrocardiography (ECG) revealing STEMI, defined as more than 30 min of continuous typical chest pain and ST-segment elevation of at least 2 mm in two contiguous ECG leads and/or left bundle branch block within 12 h of symptom onset or up to 18 h if there was evidence of continuing ischemia or hemodynamic instability. Patients were excluded if thrombolytic agents were given for the index STEMI, if they were in cardiogenic shock, had a history of stroke within a month, had end-stage renal disease, or had a life expectancy of \< 1 year from a non-cardiac condition. The study protocol was approved by the Ethics Committee of our hospital.

2.2. Analysis of patient data {#s2b}
-----------------------------

The demographic information of patients, cardiovascular history and risk factors \[smoking, hypercholesterolemia, hypertension (HT) and DM\] were obtained from the medical records. A 12-lead ECG was recorded on each patient just after hospital admission, and also the MI type was recorded from ECGs. Blood values, which were determined at hospital admission and on a daily basis during patient stay in hospital, were recorded from medical reports. Results of the first laboratory examination during the index event were used in all statistical analyses, except for the lipid profiles which were recorded from eight hour fasting period blood samples.

2.3. Coronary angiography, primary angioplasty and stenting {#s2c}
-----------------------------------------------------------

All patients received chewable aspirin (300 mg) and clopidogrel (300 mg loading dose) before coronary angiography. Prasugrel and ticagrelor were not prescribed due to unavailability and reimbursement rules of the Ministry of Health. Angiographic data of the patients were evaluated from catheter laboratory records. Emergency coronary angiography and angioplasty were performed by percutaneous femoral approach. Heparin (10000 IU) was administered when arterial access was secured. After visualizing the left and right coronary arteries, 2.5 mg of nitrate was selectively injected into the infarct related artery (IRA) to rule out possible coronary spasm. Angiographic assessments were made by visual assessment. IRA was graded according to thrombolysis in MI (TIMI) classification.[@b9] Primary angioplasty, including balloon angioplasty and/or stent implantation, was performed only for IRA according to the lesion type. For each procedure, interventional success at the acute phase was defined as reducing obstruction or stenosis to less than 50% of the IRA with TIMI 2 or 3 flow just after primary angioplasty. After angioplasty, all patients were admitted to the coronary intensive care unit, where 500 U/h of intravenous heparin or 1 mg/kg per day of subcutaneous low-molecular weight heparin were given; 100 mg aspirin and 75 mg clopidogrel were continued in all patients. Tirofiban is the only glycoprotein IIb/IIIa inhibitor used in our institution. Tirofiban was used upon high thrombus burden, thrombotic complications or slow or no-reflow conditions. Concomitant medical treatment with beta-blockers, angiotensin converting enzyme inhibitors, and statins were prescribed according to American College of Cardiology/American Heart Association guidelines. Loading doses of statins were not used.

2.4. Definition {#s2d}
---------------

Patients were evaluated according to Killip clinical examination classification.[@b10] Multi-vessel disease was defined as a presence of more than 50% lesion in at least two major epicardial coronary arteries, or left main coronary artery lesions. Patient with DM was defined as any individual with documented DM using either oral hypoglycemic agents, or insulin treatment at admission. Hypercholesterolemia was defined as total cholesterol ≥ 200 mg/dL or use of cholesterol-lowering agents. Anemia was defined as a baseline hemoglobin concentration less than 13 g/dL in men and less than 12 g/dL in women. Cardiovascular death was defined as unexplained sudden death, death owing to acute MI, heart failure, or arrhythmia. Repeat target vessel revascularization (TVR) was defined as the need of PCI, or coronary surgery, because of re-stenosis or re-occlusion of the IRA. Re-infarction was defined as an increase of creatinine kinase-MB (CK-MB) fraction more than two fold of the last value of CK-MB level and ST segment re-elevations. Long term follow-up is defined as \> 1 year.

2.5. Follow-up {#s2e}
--------------

Follow-up data were obtained from hospital records, or by interviewing the patients (directly or by telephone), their families, or their personal physicians. Major adverse cardiac events (MACEs) were defined as cardiovascular death, re-infarction, or TVR (percutaneous or surgical). Only cardiovascular mortality was recorded.

2.6. Statistical analysis {#s2f}
-------------------------

Quantitative variables were expressed as mean ± SD, and qualitative variables were expressed as percent (%). Comparison of parametric values between two groups was performed using the Student\'s *t*-test. Categorical variables were compared by the Chi-square test or Fisher\'s exact test.

Backward, stepwise, multivariate Cox regression analysis, which included variables with a *P* value of less than 0.1, was performed to identify independent predictors of in-hospital mortality. Smoking, Killip class \> 1, DM, post TIMI \< 3, ABG and admission creatinine were included in the model.

The cumulative survival curves for long-term cardiovascular mortality were constructed with the use of the Kaplan-Meier method with differences assessed with the log-rank test. A two sided *P* value of less than 0.05 was considered statistically significant. All statistical studies were carried out with SPSS program (version 15.0, SPSS, Chicago, Illinois, USA).

3. Results {#s3}
==========

The data from 677 patients with a mean age of 72.2 ± 5.4 years old who underwent primary PCI for STEMI were assessed. Mean available follow-up time was 18.8 months. Long term follow-up of eight patients in the low glucose group (LGG) and four patients in the high glucose group (HGG) were not included due to communications problems. The subjects were analyzed in subgroups according to ABG measurements (low glucose group, glucose \< 168 mg/dL and high glucose group, glucose \> 168 mg/dL). The baseline demographical, clinical, and laboratory data are demonstrated in [Tables 1](#jgc-10-04-310-t01){ref-type="table"}--[3](#jgc-10-04-310-t03){ref-type="table"}. The HGG contained more women, diabetics, smokers, and Killip class \> 1 patients (*P* \< 0.001, *P* \< 0.001, *P* = 0.04, and *P* = 0.001, respectively). Pain onset to balloon time was longer in HGG (*P* = 0.03). Peak CK-MB level and white blood cell (WBC) count were significantly higher in HGG (*P* \< 0.001 for both). Estimated glomerular filtration rate (eGFR) according to the Modification of Diet in Renal Disease (MDRD) formula.[@b11] (186 × (serum creatinine)^−1.154^ × (age)^−0.203^ × 0.742 (for females)) was lower in HGG. The rate of post TIMI \< 3 was significantly lower in HGG (*P* = 0.02). The rate of unsuccessful procedures was higher and left ventricular ejection fraction (LVEF) was lower in HGG (*P* = 0.005 and *P* \< 0.001, respectively).

In-hospital clinical events are listed in [Table 4](#jgc-10-04-310-t04){ref-type="table"}. The rate of in-hospital mortality, MACE, congestive heart failure (CHF), cardio-pulmonary resuscitation (CPR), inotropic usage, and ventricular tachycardia/ventricular fibrillation (VT/VF) were significantly higher in HGG group (*P* \< 0.001 for all). Stroke and the need for hemodialysis were significantly more frequent in HGG group (*P* = 0.02 and *P* = 0.03, respectively). Hospital in-stay time was longer (*P* = 0.04) and the rate of IABP and transient pacemaker usage were higher in HGG group (*P* = 0.002 and *P* \< 0.001, respectively).

###### Demographic and clinical properties and laboratory findings of groups.

                                  Low-glucose group (*n* = 457)   High-glucose group (*n* = 220)     *P*
  ------------------------------ ------------------------------- -------------------------------- ----------
  Male gender                              327 (71.5%)                     127 (57.7%)             \< 0.001
  Diabetes mellitus                        76 (16.6%)                       46 (20.9%)             \< 0.001
  Hypertension                             257 (56.2%)                     133 (60.4%)               0.32
  Hyperlipidemia                           118 (25.8%)                      59 (26.8%)               0.77
  Smoking                                  184 (40.2%)                       75 (34%)                0.04
  CABG                                      19 (4.1%)                        8 (3.6%)                0.76
  PCI                                       33 (7.2%)                       24 (10.9%)               0.09
  Prior MI                                  55 (12%)                        30 (13.6%)               0.55
  Killip \> 1                               27 (5.9%)                       46 (20.9%)              0.001
  Age, yrs                                 72.2 ± 5.5                        72 ± 5.2                0.64
  Pain-balloon time, h                      3.5 ± 2.5                       4.1 ± 2.8                0.03
  Door-balloon time, m                       32 ± 5                          28 ± 4.5                0.76
  Laboratory findings                                                                             
   Baseline glucose, mg/dL                128.6 ± 22.3                     248.8 ± 91.7            \< 0.001
   Baseline creatinine, mg/dL              1.08 ± 0.54                      1.18 ± 0.6               0.03
   Peak CK-MB, U/L                        205.9 ± 170.6                    267 ± 181.7             \< 0.001
   WBC, /mm^3^                             10.9 ± 3.2                       12.9 ± 4.7             \< 0.001
   Hemoglobin, g/dL                        12.8 ± 1.7                       12.4 ± 1.9              0.004
   Total cholesterol, mg/dL                178 ± 36.5                      177.5 ± 42.9              0.97
   LDL cholesterol, mg/dL                 111.1 ± 28.7                     110.8 ± 34.9              0.93
   HDL cholesterol, mg/dL                  42.9 ± 10.3                     41.4 ± 10.4               0.15
   Triglyceride, mg/dL                    115.9 ± 55.4                     122.5 ± 61.8              0.22
   eGFR (ml/min per 1.73 m^2^)             73.4 ± 21.2                     66.5 ± 23.5             \< 0.001
   Anemia                                   183 (40%)                        95 (43%)                0.38

Variables are reported as mean ± SD or *n* (%). CABG: coronary artery by-pass grafting; CK-MB: creatinine kinase-MB; eGFR; estimated glomerular filtration rate; HDL: high density lipoprotein; LDL: low density lipoprotein; MI: myocardial infarction; PCI: primary coronary intervention; WBC: white blood cell count.

Long term follow-up results of the patients are provided in [Table 5](#jgc-10-04-310-t05){ref-type="table"}. Long term follow-up results of eight patients in LGG and four patients of HGG could not be obtained. Death, re-infarction and MACE were significantly higher in HGG (*P* \< 0.001 for all).

Results of univariate and multivariate logistic regression analysis for the prediction of in-hospital MACE are shown in [Table 6](#jgc-10-04-310-t06){ref-type="table"}. Univariate regression analysis showed a correlation between DM, smoking, Killip \> 1, post TIMI \< 3, ABG, admission creatinine, and in-hospital adverse cardiac events.

###### Comparison of studied groups\' coronary angiography results.

                        Low glucose group (*n* = 457)   High glucose group (*n* = 220)   *P*
  -------------------- ------------------------------- -------------------------------- ------
  Culprit lesion                                                                        
   LMCA                            0 (0%)                          2 (0.9%)             
   LAD                           219 (47.9%)                      119 (54%)             
   CX                            56 (12.3%)                       18 (8.3%)              0.07
   RCA                           179 (39.1%)                      78 (35.5%)            
   Others                         3 (0.7%)                         3 (1.3%)             
  Vessel                                                                                
   1                             149 (32.6%)                      67 (30.4%)            
   2                             162 (35.4%)                      71 (32.2%)             0.37
   3                              146 (32%)                       82 (37.4%)            
  Pre TIMI                                                                              
   0−1                           405 (88.6%)                      198 (90%)             
   2                              35 (7.6%)                        13 (6%)               0.71
   3                              18 (3.8%)                         8 (4%)              
  Post TIMI                                                                             
   0−1                           56 (12.3%)                        44 (20%)             
   2                              26 (5.7%)                       16 (7.3%)              0.02
   3                              375 (82%)                      160 (72.7%)            
  Stent implantation             360 (78.8%)                      165 (75%)              0.27

Variables are reported as *n* (%). CX: circumflex artery; LAD: left anterior descendant artery; LMCA: left main coronary artery; RCA: right coronary artery, TIMI: thrombolysis in myocardial infarction.

###### Comparison of coronary angiographic findings and ejection fraction of groups.

                            Low glucose group (*n* = 457)   High glucose group (*n* = 220)     *P*
  ------------------------ ------------------------------- -------------------------------- ----------
  Unsuccessful procedure              58 (12%)                         46 (20%)               0.005
  Tirofiban use                      209 (45.7%)                      94 (42.7%)               0.51
  Stent                                                                                     
   Diameter                          3.1 ± 0.35                      3.04 ± 0.33               0.03
   Length                            19.2 ± 6.5                       20.1 ± 7.5               0.13
  Ejection fraction                  46.8 ± 10.7                     41.4 ± 12.6             \< 0.001

Variables are reported as mean ± SD or *n* (%).

On the other hand, multivariate regression analysis demonstrated that Killip \> 1, post TIMI \< 3, ABG, and admission creatinine were independent predictors of in-hospital adverse cardiac events.

###### Comparison of in-hospital events of groups.

                            Low glucose group (*n* = 457)   High glucose group (*n* = 220)     *P*
  ------------------------ ------------------------------- -------------------------------- ----------
  Death                                23 (5%)                         41 (18%)              \< 0.001
  Re-infarction                        10 (2%)                         6 (2.7%)                0.66
  TVR                                  19 (4%)                        14 (5.4%)                0.21
  MACE                                 38 (8%)                        49 (22.2%)             \< 0.001
  Stroke                               5 (1%)                          8 (3.6%)                0.02
  CPR                                 24 (5.2%)                       47 (21.3%)             \< 0.001
  Hemodialysis                        4 (0.8%)                         7 (3.1%)                0.03
  VT/VF                                14 (3%)                        40 (18.1%)             \< 0.001
  CHF                                 78 (17%)                        72 (32.7%)             \< 0.001
  Inotrope use                        41 (8.9%)                       56 (25.5%)             \< 0.001
  IABP                                9 (1.9%)                        45 (20.5%)             \< 0.001
  Atrial fibrillation                 21 (4.5%)                       10 (4.5%)                0.06
  Transient pacemaker                 21 (4.5%)                       24 (10.9%)              0.002
  Transfusion                         31 (6.7%)                       23 (10.5%)               0.09
  Hospital in-stay (day)              7.7 ± 4.3                       8.6 ± 6.1                0.04

Variables are reported as mean ± SD or *n* (%). CPR: cardio-pulmonary resuscitation; IABP: intra-aortic balloon pump; MACE: major adverse cardiac event; TVR: target vessel revascularization, VT/VF; ventricular tachycardia/ventricular fibrillation.

###### Comparison of long-term events of groups.

                   Low glucose group (*n* = 426)   High glucose group (*n* = 175)    *P*
  --------------- ------------------------------- -------------------------------- -------
  Death                      41 (9.6%)                        35 (20%)              0.001
  Stroke                     5 (1.1%)                         2 (1.1%)              0.95
  CHF                       50 (11.7%)                       26 (14.9%)             0.18
  Re-infarction              26 (6.1%)                       24 (13.7%)             0.001
  TVR                       59 (13.8%)                       24 (13.7%)             0.76
  MACE                      95 (22.3%)                       60 (34.2%)             0.001

Variables are reported as *n* (%). CHF: congestive heart failure; MACE: major adverse cardiac events; TVR: target vessel revascularization.

###### Effects of multiple variables on in-hospital MACE in univariate and multivariate logistic regression analyses.

                    Univariate analysis   Multivariate analysis                                    
  ---------------- --------------------- ----------------------- ---------- ------- -------------- ----------
  DM                        5.1                2.88--9.03         \< 0.001                         
  Smoking                   1.8               1.066--3.146          0.03                           
  KILLIP \> 1              15.6                 8.3--26.7         \< 0.001   7.96     3.7--16.9     \< 0.001
  Post TIMI \< 3           9.04                 5.2--15.7         \< 0.001   4.74      2.2--10      \< 0.001
  ABG (mg/dL)              1.009              1.007--1.012        \< 0.001   1.007   1.003--1.011   \< 0.001
  AC (mg/dL)                3.1                 1.94--4.9         \< 0.001   1.78     1.18--2.7      0.006

ABG: admission blood glucose; AC: admission creatinine; DM: diabetes mellitus; TIMI: thrombolysis in myocardial infarction.

The receive-operating characteristic (ROC) curve with regard to MACE is shown in [Figure 1](#jgc-10-04-310-g001){ref-type="fig"}. An ABG level of \> 168 mg/dL was identified as an effective cut-point in STEMI of MACE (area under curve = 0.76, 95% confidence interval (CI): 0.7--0.82, *P* \< 0.001). Long term survival curve of the studied groups is found in [Figure 2](#jgc-10-04-310-g002){ref-type="fig"}. The rate of low glucose group survival was significantly lower (*P* \< 0.001).

![The receive-operating characteristic (ROC) curve of admission blood glucose with regard to major adverse cardiac events.](jgc-10-04-310-g001){#jgc-10-04-310-g001}

![Long-term survival curve of studied groups.\
Low glucose group: patients with admission blood glucose level ≤ 168 mg/dL; high glucose group: patients with admission blood glucose \> 168 mg/dL. Mean available follow-up time was 18.8 months. Long follow-up of 8 patients in low glucose group and 4 patients in high glucose group were not done due to any communications problems.](jgc-10-04-310-g002){#jgc-10-04-310-g002}

4. Discussion {#s4}
=============

The present study, based on a non-selected cohort of elderly patients hospitalized with STEMI, highlights an important potential relevance of hyperglycemia on admission to accurately identify a group of elderly patients at high risk for both short-term and long-term outcomes. These findings are consistent with various previous studies.[@b2]--[@b7] Although ABG is well known as an independent predictor of in-hospital adverse events and mortality in the patients with STEMI, there is limited data in the elderly population which constitute an increasingly important proportion of patients in recent years. Our study indicates that the ABG level may be an independent predictor of worse prognosis in the elderly STEMI patients, as in the general STEMI population

An elevated ABG level is common in patients with ACSs in both diabetic and non-diabetic patients and has been studied in various studies. Dırkali *et al*.[@b5] analyzed the relationship of ABG and major complications in patients with ACSs and suggested ABG as an independent and powerful predictor of in-hospital and late outcomes. Kosiborod *et al.*[@b6] reported admission hyperglycemia was more accurately associated with in-hospital and long-term morbidity and mortality in non-diabetic patients than in diabetic patients. In three different studies by Hoebers *et al*.[@b12], Ishihara *et al*.[@b13], and Rasoul *et al*.[@b14] it was proposed that a high ABG level was associated with increased in-hospital, but not long-term mortality (\> 30 days). Hoebers *et al*.[@b12] and Knudsen *et al*.[@b15] explained these findings by acute deterioration of glucose metabolism. After the acute phase of MI, glucose intolerance may resolve and long-term mortality does not seem to be affected by glucose metabolism.[@b12],[@b16] In our study, we showed that in-hospital and long term mortalities were higher in elderly of the HGG ([Figure 2](#jgc-10-04-310-g002){ref-type="fig"}, *P* \< 0.001).

Yang, *et al*.[@b17] demonstrated that impaired glucose metabolism is closely related to other cardiovascular risk factors. These subjects with impaired glucose metabolism may easily develop stress diabetes during stressful conditions like acute coronary syndromes. However, subjects in the HGG had less cardiovascular risk factors compared to the individuals in the LGG. This finding may strengthen the importance of ABG as a prognostic indicator in our study.

Post PCI TIMI frame and unsuccessful primary interventions, in our study, were significantly lower in the HGG (*P* \< 0.01 and *P* = 0.05, respectively). It had been shown that elevated ABG levels in non-diabetic patients is associated with micro-vascular obstruction and causes larger infarcts which result in worse outcomes like left ventricular dysfunction and increased in-hospital MACE.[@b18]

Even in normal subjects, acute hyperglycemia causes various changes like prolongation of corrected QT interval and reduced nitric oxide availability.[@b19],[@b20] These may result in detrimental hemodynamic changes and may lead to cardiac arrhythmias and sudden death. In our study, arrhythmias were more frequently seen in HGG (*P* \< 0.01). One of the reasons for higher mortality in patients with higher glucose levels may be the increased susceptibility to arrhythmias.

In the acute phase of MI, higher glucose levels are usually seen and result in insulin resistance, higher free fatty acid concentrations, and impaired myocardial glucose usage which causes increased oxygen consumption and probably worsens ischemia.[@b21],[@b22] In some clinical studies, it has been shown that tight glycemic control with insulin, insulin-glucose and insulin-glucose-potassium infusions may decrease mortality in acute MI and critically ill patients.[@b23]--[@b26] However, these treatment strategies may potentially cause volume overload, hyperglycemia and/or hypoglycemia.[@b27],[@b28]

A meta-analysis, including 15 trials which examined stress hyperglycemia and in-hospital mortality, showed that stress hyperglycemia in MI is associated with an increased risk of in-hospital mortality in patients with, and without, DM.[@b29] The risk of congestive heart failure or cardiogenic shock was also increased in patients without DM. Similarly, Ishihara *et al*.[@b30] found that higher ABG in acute MI is related with lower LVEF. Heart failure is associated with insulin resistance and glucose intolerance.[@b31],[@b32] This may be one of the factors that explain the relation between acute hyperglycemia and increased in-hospital mortality. In this study, patients in HGG had an increased rate of Killip Class \>1 (*P* = 0.001) and lower LVEF (*P* \< 0.001). Furthermore, CHF and inotropic agent usage were significantly more frequent in HGG (*P* \< 0.001 for both). Yang *et al*.[@b33] found a linear correlation between higher ABG and Killip classification in a study conducted in elderly patients with acute MI.

The prospective design and the absence of an evaluation of the course of stress hyperglycemia are main limitations of our study. Thus, we could not draw any conclusions about how the course of glycemia affected the long-term outcomes. The unavailability of HgA1c levels hampers discrimination between undiagnosed type 2 diabetes and stress diabetes.

In conclusion, a higher level of ABG may be linked with poor post-procedural myocardial perfusion, lower LVEF, higher in-hospital and long term mortality, and MACE in older patients with STEMI who underwent primary PCI. ABG levels could be used for a better risk stratification of elderly patients.
